SLU-PP-915: the orally active exercise-mimetic ERR agonist
A next-generation, orally bioavailable pan-ERR agonist from the same lab as SLU-PP-332: what the preclinical science shows, how it differs from 332, and the honest gaps. Animal data only; no human studies exist.
Animal data only as of 2026
SLU-PP-915 is an orally bioavailable pan-ERR agonist that activates all 3 ERR isoforms (α, β and γ), from the Saint Louis University lab behind SLU-PP-332, studied as an exercise mimetic. In mice, injected 915 enhanced aerobic exercise capacity to a similar extent as injected 332. With 0 human trials, human safety, dosing and efficacy are unknown.
Track your vials and inventory on paper
Printable vial and inventory sheets for your own research records. Every value is entered by you. Free to build and preview; $5/month to unlock printing.
How It Works
Activates all three estrogen-related receptors (ERRα, β, γ), orphan nuclear receptors that drive mitochondrial biogenesis, oxidative phosphorylation, fatty-acid oxidation and the Krebs cycle, and are essential for skeletal-muscle adaptation to aerobic exercise. SLU-PP-915 was identified through the pharmacological evaluation of a new, potent pan-ERR chemical series. [PMID 37421886, 41421047]
A chemically distinct compound that, unlike SLU-PP-332, is orally bioavailable in mice. In mice, injected 915 enhanced aerobic exercise capacity (distance and duration) to a similar extent as injected 332, and oral 915 kept comparable efficacy once adjusted for systemic exposure. Oral bioavailability is the main difference from 332 that this paper reports. [PMID 41421047, 37421886]
In mice, 915 (like 332) robustly induces DDIT4 (an acute-aerobic-exercise gene) to levels matching or exceeding treadmill running, depending on the muscle examined, and synergizes with exercise training to further enhance DDIT4 and mitochondrial gene expression. [PMID 41421047]
Across the SLU-PP series, pan-ERR agonism raises energy expenditure and fatty-acid oxidation and improves insulin sensitivity in metabolic-syndrome models (SLU-PP-332), and novel pan-ERR agonists ameliorate heart failure by enhancing cardiac fatty-acid metabolism and mitochondrial function. All animal data. [PMID 37739806, 37961903]
What the Data Shows
SLU-PP-915 vs SLU-PP-332: What Actually Differs
Both are pan-ERR agonist "exercise mimetics" from the same Saint Louis University lab (Burris). The meaningful difference is the route of activity, not the target. Everything below is animal / in-vitro data: neither compound has been tested in people (332 has one ex-vivo study in muscle cells from human biopsies; Source 7).
| SLU-PP-915 | SLU-PP-332 | |
|---|---|---|
| Target | Pan-ERR agonist (ERRα/β/γ) | Pan-ERR agonist (ERRα/β/γ) |
| Oral bioavailability | Yes, orally active in mice | No, lacks oral bioavailability in mice |
| Aerobic exercise capacity (mice) | Increased; similar to 332 when both injected, oral comparable after adjusting for exposure | Increased (injected) |
| Exercise-gene induction | DDIT4 to running levels; with training, further DDIT4 + mitochondrial gene expression | Upregulates exercise-responsive genes |
| Human data | No human trials; in-vitro metabolism in human liver S9/microsomes only (Source 3) | No human trials; one ex-vivo study on human muscle cells (Source 7) |
| Approval status | Drug candidate under investigation; not an approved drug (Source 3) | Drug candidate under investigation; not an approved drug (Source 3) |
Key Takeaways
- SLU-PP-915 is a pan-ERR agonist (activates ERRα, β and γ), with the same target family and lab (Saint Louis University / Burris) as SLU-PP-332.
- The main difference from SLU-PP-332 reported so far is oral bioavailability: in mice 915 is orally bioavailable, while 332 lacks oral bioavailability.
- In mice, injected 915 enhances aerobic exercise capacity (running distance and duration) to a similar extent as injected 332, and oral 915 keeps comparable efficacy once adjusted for systemic exposure.
- It induces the acute-exercise gene DDIT4 to levels matching or exceeding treadmill running (depending on the muscle), and combined with training it further enhances DDIT4 and mitochondrial gene expression.
- Across the SLU-PP series, pan-ERR agonism improves metabolic-syndrome markers and ameliorates heart failure in animal models.
- A sports drug-testing study has already mapped 915's in-vitro metabolites, citing its possible illicit use as a performance-enhancing substance (Source 3).
- No human trials: SLU-PP-915 has never been tested in people. The only human-derived material is human liver S9 fraction and microsomes in an in-vitro metabolism study (Source 3). Safety, dosing and efficacy in people are entirely unknown.
- No human dose exists. There is no established protocol, and nothing here is a dosing recommendation.
- No long-term safety profile; the effects of chronic ERR activation in humans are uncharacterized.
- Not approved and not a supplement. It is an early-stage research compound with no approved use.
- Whether the mouse exercise-mimetic effect translates to human fitness, fat loss or disease outcomes is entirely unproven.
Frequently Asked Questions
What is SLU-PP-915?
SLU-PP-915 is a synthetic pan-ERR agonist ("exercise mimetic") developed at Saint Louis University — an orally bioavailable pan-ERR agonist, chemically distinct from SLU-PP-332, that activates the ERRα/β/γ nuclear receptors regulating mitochondrial and fatty-acid-oxidation genes. All published data is from animal and in-vitro studies.
How is SLU-PP-915 different from SLU-PP-332?
Same pan-ERR mechanism, but in mice 915 is orally bioavailable whereas 332 is not. In mice, injected 915 enhanced aerobic exercise capacity to a similar extent as injected 332, and oral 915 kept comparable efficacy once adjusted for systemic exposure.
Is SLU-PP-915 an exercise mimetic?
In mice it induces the acute-exercise gene DDIT4 to levels matching or exceeding treadmill running without exercise, and combined with training it further enhances DDIT4 and mitochondrial gene expression — but there is no human evidence it can replace exercise.
Is there any human data on SLU-PP-915?
No. There are no human trials — SLU-PP-915 has never been tested in people. All published work is preclinical (mouse and in-vitro); the only human-derived material is human liver S9 fraction and liver microsomes used in an in-vitro metabolism study (Source 3). Human safety, dosing and efficacy are unknown, and there is no recommended dose.
Is SLU-PP-915 detectable in drug testing?
Anti-doping researchers have already mapped its in-vitro metabolites for sports drug-testing programs, work the authors say may help uncover its illicit use as a performance-enhancing substance.
Related compound: SLU-PP-332
Swiss Chems does not list SLU-PP-915. It lists SLU-PP-332, the related compound from the same Saint Louis University lab compared above (a different compound, not SLU-PP-915). Swiss Chems sells it as capsules, but the mouse study cited above reports that SLU-PP-332 lacks oral bioavailability (Source 2), and it has no human dose or safety data. HighPeptides earns a commission on purchases. Lab-test standing and regulatory notices for every vendor we track, including this one, are on our vendors page.
SLU-PP-332 (not SLU-PP-915) at Swiss Chems →Affiliate links support HighPeptides at no extra cost.
Recommended Products
General mitochondrial and endurance supplements, not a protocol for, or a substitute for, SLU-PP-915.
Affiliate links support HighPeptides at no extra cost.
Related HighPeptides Research
Peer-Reviewed References
67-page guide: protocols, dosing, sourcing. Everything in one place.
Get the guide: $19 (normally $29) → The Peptide Buyer’s Playbook ($19) The Peptide Buyer’s Playbook ($19) All ebooks & guides →Educational purposes only. Not medical advice.
SLU-PP-915 is an early-stage research chemical with no human clinical data. It has not been tested in humans; there is no established dose, no safety profile, and no efficacy claim can be made for human use. Nothing here, including the vendor link above, is a recommendation to obtain or take SLU-PP-915 or SLU-PP-332; neither has a human dose or safety profile. Do not self-administer either compound.
Get the Free 2026 Peptide Protocol Stack
Twelve compounds across four pillars: metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.